Published in Hepatitis Weekly, March 24th, 2008
"Pegylated IFN-alpha (PEG-IFN) emerged and comibination therapy including PEG-IFN and ribavirin has become the mainstay of treatment. However, the combination is associated with a high discontinuation rate, frequent dose modifications, low tolerability and a high nonresponder rate. In the continued search...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.